Orchid Pharma Limited — Investor Meet, 16-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Orchid Pharma's Q3 sales dipped 5% YoY to INR207 Cr, with 9-month sales down 16% to INR574 Cr. Q3 EBITDA margin was 6% (vs 17% YoY), pressured by continued global antibiotic pricing stress and lower regulated market contribution. Oral segment faced 12% price erosion (9M). Strategic initiatives are progressing: Exblifep has signed new term sheets and commenced sales in Spain, Italy, UAE, and Kuwait. The 7ACA project is on target for mechanical completion by September. Management noted "green shoots" in January and maintains an optimistic outlook, focusing on differentiated products for long-term value.